Are most thyroid nodules cancerous?

No. Approximately 90–95% of thyroid nodules are benign, and malignancy is found in only about 4–8% of nodules that undergo biopsy. Biopsy is not recommended for every nodule — it is reserved for those with ultrasound features that raise concern, based on ACR TI-RADS or similar risk-stratification systems. The primary challenge is identifying the small minority that need further investigation without over-testing the many that pose no malignancy risk.

Do thyroid nodules need to be removed?

Most thyroid nodules do not need to be removed. Benign nodules without symptoms can be safely monitored with periodic ultrasound, typically every 1–2 years. Surgery is considered for nodules causing compressive symptoms, those with indeterminate or malignant cytology, autonomously functioning nodules causing hyperthyroidism, or high-risk molecular test results. Radiofrequency ablation (RFA) is an increasingly available minimally invasive alternative to surgery for large symptomatic benign solid nodules at select Canadian centres.

Can a thyroid nodule affect thyroid hormone levels?

Most thyroid nodules do not affect hormone levels — thyroid function tests are normal in the majority of people with nodules. A small proportion are autonomously hyperfunctioning (hot) nodules that produce thyroid hormone independently of TSH stimulation; when large enough, these can suppress TSH and cause hyperthyroidism. Nodules found in the context of Hashimoto's thyroiditis may coexist with hypothyroidism, but the nodules themselves do not directly cause the hormone deficiency.

How often do thyroid nodules grow, and when does growth matter?

Most benign thyroid nodules grow slowly or not at all. Research published in JAMA found that approximately 80% of benign nodules remain stable on follow-up, about 15% shrink, and only roughly 5% grow significantly. Growth that raises concern — and may prompt re-biopsy — is defined as an increase of 20% or more in two dimensions over 6 months, or an increase of more than 2 mm in two dimensions on serial ultrasound.

Is thyroid nodule evaluation covered by provincial health insurance in Canada?

Yes, in most provinces. A physician-ordered TSH blood test and neck ultrasound for a clinically identified or suspected thyroid nodule are generally covered under provincial health plans, including through LifeLabs and Dynacare collection sites. Fine needle aspiration biopsy performed in a hospital or outpatient clinic setting is also typically covered. Molecular testing (ThyroSeq, Afirma) for indeterminate biopsy results is not universally covered and may require out-of-pocket payment or private insurance, depending on the province and the ordering institution.

Thyroid nodules — Glossary

What it is

Thyroid nodules are discrete solid or fluid-filled lumps that form within the thyroid gland — the butterfly-shaped gland at the base of the front of the neck. On high-resolution ultrasound, they are detected in approximately 20–76% of the general population, making them one of the most common incidental findings in clinical medicine. The critical clinical fact is that roughly 90–95% of thyroid nodules are benign; malignancy is found in approximately 4–8% of nodules that undergo biopsy, with rates slightly higher in men than women. In Canada, thyroid nodules are evaluated and managed according to frameworks aligned with the American Thyroid Association (ATA) 2015 guidelines and the ACR TI-RADS ultrasound classification system, both of which are widely used by Canadian endocrinologists and radiologists. Most nodules are found incidentally — during a routine physical exam, a neck ultrasound ordered for another reason, or carotid imaging — rather than because of symptoms.

Thyroid nodules (also called thyroid lumps or thyroid masses) are distinct from diffuse thyroid enlargement (goitre), though multinodular goitre is itself a common cause of nodule formation.

Causes and mechanism

Thyroid nodules arise when thyroid follicular cells proliferate abnormally or when fluid accumulates within the gland. Several underlying conditions drive this process:

Cause	Key features	Malignancy risk
Multinodular goitre	Multiple nodules; most common overall cause; linked to iodine insufficiency, genetics, autoimmunity	Low
Thyroid cyst	Fluid-filled; often colloid or degenerative	Very low
Follicular adenoma	Benign encapsulated tumour of follicular cells	Very low
Hashimoto's thyroiditis	Autoimmune inflammation produces heterogeneous nodular texture on ultrasound	Low (background risk)
Hyperfunctioning (hot) nodule	Autonomously produces thyroid hormone independent of TSH; almost never malignant	Negligible
Thyroid cancer	Papillary (most common), follicular, medullary, or anaplastic types	By definition 100%

Women are approximately four times more likely than men to develop thyroid nodules, and prevalence rises with age. Other risk factors for nodule formation include iodine deficiency, family history of thyroid disease, and prior radiation exposure to the head or neck. Risk factors that raise concern for malignancy within a nodule include male sex, age under 20 or over 60, a personal or family history of thyroid cancer or multiple endocrine neoplasia (MEN) syndrome, prior head and neck radiation, and rapid nodule growth or firmness on examination.

Symptoms and diagnosis

The vast majority of thyroid nodules produce no symptoms. When symptoms do occur, they typically reflect either the physical size of the nodule or its effect on thyroid hormone output:

Visible or palpable lump at the front of the neck
Pressure, tightness, or fullness in the neck
Difficulty swallowing (with large nodules compressing the esophagus)
Hoarse voice (from pressure on the recurrent laryngeal nerve)
Symptoms of hyperthyroidism — palpitations, unexplained weight loss, tremor, heat intolerance — when a nodule is autonomously hyperfunctioning

Diagnostic workup follows a structured sequence:

TSH measurement — the first blood test. A suppressed TSH suggests a hyperfunctioning nodule; a normal or elevated TSH does not distinguish benign from malignant.
Neck ultrasound — the primary imaging tool. Assesses size, echogenicity, calcification pattern, shape, borders, and vascularity. ACR TI-RADS or EU-TIRADS scoring determines which nodules warrant biopsy. In Canada, LifeLabs and Dynacare both perform thyroid ultrasound, and most provincial health plans cover it when ordered by a physician.
Fine needle aspiration biopsy (FNAB) — the key diagnostic test for nodules meeting biopsy criteria. Performed under ultrasound guidance; results are reported using the Bethesda classification (I–VI).
Radionuclide thyroid scan — used when TSH is suppressed, to confirm whether a nodule is hyperfunctioning (hot) and therefore almost certainly benign.
Molecular testing — for cytologically indeterminate results (Bethesda III/IV), platforms such as ThyroSeq and Afirma help estimate malignancy risk and guide the decision between surveillance and surgery.

Treatment options

Management depends on the nodule's functional status, cytology result, and whether it causes symptoms.

Benign nodules (Bethesda II): Most require only periodic ultrasound surveillance — typically every 1–2 years. Surgery or ablation is considered for nodules causing compressive symptoms or significant cosmetic concern. Radiofrequency ablation (RFA) and laser ablation are increasingly available in Canada as minimally invasive alternatives to surgery for large symptomatic benign solid nodules.

Indeterminate nodules (Bethesda III/IV): Molecular testing is used to further stratify risk. Surgical lobectomy is recommended when molecular results suggest elevated malignancy risk or when diagnostic uncertainty persists.

Malignant nodules (Bethesda V/VI): Surgical resection (thyroidectomy or hemithyroidectomy depending on risk category) is the primary treatment, followed by radioactive iodine and levothyroxine suppression therapy where indicated by tumour stage and histology.

Hyperfunctioning (hot) nodules: Treated with radioactive iodine ablation or surgery to address the resulting hyperthyroidism. Biopsy is generally not required, as hot nodules carry negligible malignancy risk.

When to see a clinician in Canada

Seek assessment promptly if you notice a new or enlarging lump at the front of the neck, hoarseness or voice change lasting more than two weeks, new difficulty swallowing, or symptoms consistent with hyperthyroidism (rapid heartbeat, unexplained weight loss, tremor, heat intolerance). If a nodule has already been found incidentally — on imaging done for another reason — and has not yet been evaluated with thyroid function tests and a neck ultrasound, that follow-up is important to ensure appropriate risk stratification.

In Canada, initial assessment is typically done by a family physician, who can order TSH and refer for ultrasound. Endocrinology or general surgery referral is appropriate when biopsy, molecular testing, or intervention is being considered. Telehealth platforms such as Felix, Maple, Cleo, and Phoenix can facilitate initial consultation and referral coordination, though in-person examination and imaging remain necessary for full evaluation.

Limitations and open questions

Research is still emerging on the optimal surveillance interval for benign nodules — current recommendations (every 1–2 years) are based on observational data rather than randomized trials, and some guidelines are moving toward less frequent follow-up for low-risk nodules. The role of molecular testing platforms (ThyroSeq, Afirma) in Canadian practice is not yet uniformly standardized, and access varies by province and centre. Health Canada has not issued a standalone national guideline on thyroid nodule management; Canadian clinicians generally follow ATA 2015 guidance, which is due for an update. The long-term outcomes of radiofrequency ablation compared with surgery for benign nodules are still being established in prospective studies. Finally, the relationship between thyroid nodule formation and environmental exposures — including microplastics and endocrine-disrupting chemicals — is an active area of investigation without definitive conclusions.

Thyroid nodules